Psychiatry and Neurology, Neurology · Springfield, OR
NPI
1578760278
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1 Hayden Bridge Way
Springfield, OR, 97477
Phone (541) 868-9430
Groups this clinician bills Medicare through
Medicare paid, 2024
$173K
19,429 services
Medicare patients, 2024
357
Average age 70
Drug cost, 2024
$4.4M
3,707 prescriptions
Company payments, 2025
$267K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David A Clark was code J0585 (injection, onabotulinumtoxina, 1 unit), 18,190 times for 29 patients. In total David A Clark billed 19,429 services in 12 codes, and Medicare paid $173K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 18,190 | 29 | $4.64 | $84K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 277 | 202 | $12.14 | $3,363 |
| 99215 Office E&M - Established | Office | 236 | 155 | $126.11 | $30K |
| 99214 Office E&M - Established | Office | 235 | 173 | $83.41 | $20K |
| 92133 Computerized Ophthalmic Imaging | Office | 108 | 89 | $24.75 | $2,673 |
| 92283 Ophthalmological E&M | Office | 94 | 76 | $38.92 | $3,659 |
| 64615 Musculoskeletal | Office | 88 | 27 | $111.13 | $9,779 |
| 92083 Vision, Hearing, and Speech Services | Office | 84 | 69 | $41.25 | $3,465 |
| 99205 Office E&M - New | Office | 80 | 80 | $151.58 | $12K |
| 99204 Office E&M - New | Office | 30 | 30 | $110.63 | $3,319 |
By year: 2022 $172K for 19,210 services; 2023 $176K for 17,976 services; 2024 $173K for 19,429 services.
Medicare prescription drug claims, 2024
In 2024, the drug David A Clark prescribed most often to Medicare patients was Gabapentin, with 350 prescriptions and refills. In total David A Clark wrote 3,707 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 350 | 671 | 94 | $8,191 |
| Baclofen Generic | 214 | 326 | 49 | $4,711 |
| Pyridostigmine Bromide Generic | 167 | 335 | 48 | $18K |
| Prednisone Generic | 166 | 270 | 42 | $1,323 |
| Vumerity Diroximel Fumarate | 111 | 111 | 12 | $1.0M |
| Topiramate Generic | 109 | 206 | 22 | $1,075 |
| Teriflunomide Generic | 97 | 107 | 16 | $95K |
| Kesimpta Pen Ofatumumab | 91 | 101 | Under 11 | $981K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 89 | 202 | 37 | $3,295 |
| Modafinil Generic | 78 | 111 | 17 | $6,860 |
| Tizanidine Hcl Generic | 78 | 136 | 17 | $3,012 |
| Levetiracetam Generic | 78 | 162 | 22 | $2,571 |
| Sumatriptan Succinate Generic | 61 | 68 | 15 | $840 |
| Donepezil Hcl Generic | 59 | 97 | 13 | $493 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 58 | 58 | Under 11 | $1,275 |
Brand drugs: - claims; generic drugs: 3,097 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David A Clark $267K ($267K in general payments such as food, travel and fees) from 14 companies. The largest payer was TG Therapeutics, Inc. with $55K.
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. TGTX | 38 | $55K |
| Janssen Biotech, Inc. JNJ | 48 | $40K |
| Alexion Pharmaceuticals, Inc. AZN | 50 | $36K |
| UCB, Inc. UCB.BR | 54 | $35K |
| Argenx US, Inc. ARGX | 52 | $33K |
| Biogen, Inc. BIIB | 24 | $31K |
| Amgen Inc. AMGN | 23 | $22K |
| Abbvie Inc. ABBV | 14 | $12K |
| Vanda Pharmaceuticals Inc. VNDA | 6 | $3,050 |
| Genzyme Corporation SNY | 7 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.